CTLA4-FasL fusion product suppresses proliferation of fibroblast-like synoviocytes and progression of adjuvant-induced arthritis in rats

Molecular Immunology

Volumn 50, Issue 3, 2012, Pages 150-159

  Zhang, Wei ^a   Wang, Bo ^a   Wang, Fang ^a   Zhang, Jin ^a   Yu, Jiyun ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Animal model; Gene therapy; Proteins; Rheumatoid arthritis; Synoviocytes

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; PARVOVIRUS VECTOR; RECOMBINANT CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 FASL PROTEIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DISEASE COURSE; DISEASE SEVERITY; DRUG BINDING; DRUG EFFECT; FEMALE; GENE TARGETING; GENE TRANSFER; HISTOLOGY; IMMUNIZATION; IN VITRO STUDY; INFLAMMATION; JOINT SWELLING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SYNOVIOCYTE; SYNOVIUM; T LYMPHOCYTE ACTIVATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL PROLIFERATION; CELLS, CULTURED; CTLA-4 ANTIGEN; CYTOKINES; DISEASE PROGRESSION; DOWN-REGULATION; FAS LIGAND PROTEIN; FEMALE; FIBROBLASTS; RATS; SYNOVIAL MEMBRANE;

ADENO-ASSOCIATED VIRUS; ANIMALIA; RATTUS;

EID: 84862829145     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.01.007     Document Type: Article

References (38)

1. Adriaansen J., Vervoordeldonk M.J., Tak P.P. Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology 2006, 45:656-668.
2. Bartok B., Firestein G.S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol. Rev. 2010, 233:233-255.
3. Bennett J.C. The role of T lymphocytes in rheumatoid arthritis and other autoimmune diseases. Arthritis Rheum. 2008, 58:53-57.
4. Bluestone J.A., St Clair E.W., Turka L.A. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006, 24:233-238.
5. Collette Y., Benziane A., Razanajaona D., Olive D. Distinct regulation of T-cell death by CD28 depending on both its aggregation and T-cell receptor triggering: a role for Fas-FasL. Blood 1998, 92:1350-1363.
6. Cope A.P., Schulze-Koops H., Aringer M. The central role of T cells in rheumatoid arthritis. Clin. Exp. Rheumatol. 2007, 25:S4-S11.
7. Dranitzki-Elhalel M., Huang J.H., Rachmilewitz J., Pappo O., Parnas M., Schmidt W., Tykocinski M.L. CTLA-4. FasL inhibits allogeneic responses in vivo. Cell Immunol. 2006, 239:129-135.
8. Elhalel M.D., Huang J.H., Schmidt W., Rachmilewitz J., Tykocinski M.L. CTLA-4. FasL induces alloantigen-specific hyporesponsiveness. J. Immunol. 2003, 170:5842-5850.
9. Fang J., Qian J.J., Yi S., Harding T.C., Tu G.H., VanRoey M., Jooss K. Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol. 2005, 23:584-590.
10. Feng Y.G., Jin Y.Z., Zhang Q.Y., Hao J., Wang G.M., Xie S.S. CTLA4-Fas ligand gene transfer mediated by adenovirus induce long-time survival of murine cardiac allografts. Transplant. Proc. 2005, 37:2379-2381.
11. Goater J., Müller R., Kollias G., Firestein G.S., Sanz I., O'Keefe R.J., Schwarz E.M. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. J. Rheumatol. 2000, 27:983-989.
12. Huang J.H., Tykocinski M.L. CTLA-4-Fas ligand functions as a trans signal converter protein in bridging antigen-presenting cells and T cells. Int. Immunol. 2001, 13:529-539.
13. Huber L.C., Distler O., Tarner I., Gay R.E., Gay S., Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 2006, 45:669-675.
14. Jin Y., Qu A., Wang G.M., Hao J., Gao X., Xie S. Simultaneous stimulation of Fas-mediated apoptosis and blockade of costimulation prevent autoimmune diabetes in mice induced by multiple low-dose streptozotocin. Gene Ther. 2004, 11:982-991.
15. Kayagaki N., Kawasaki A., Ebata T., Ohmoto H., Ikeda S., Inoue S. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 1995, 182:1777-1783.
16. Lu L., Qian S., Hershberger P.A., Rudert W.A., Lynch D.H., Thomson A.W. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J. Immunol. 1997, 158:5676-5684.
17. Mor A., Abramson S.B., Pillinger M.H. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin. Immunol. 2005, 115:118-128.
18. Nakajima T., Aono H., Hasunuma T., Yamamoto K., Shirai T., Hirohata K., Nishioka K. Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum. 1995, 38:485-491.
19. Noel P.J., Boise L.H., Green J.M., Thompson C.B. CD28 costimulation prevents cell death during primary T cell activation. J. Immunol. 1996, 157:636-642.
20. Okamoto H., Shidara K., Hoshi D., Kamatani N. Anti-arthritis effects of vitamin K(2) (menaquinone-4)-a new potential therapeutic strategy for rheumatoid arthritis. FEBS J. 2007, 274:4588-4594.
21. Okamoto K., Asahara H., Kobayashi T., Matsuno H., Hasunuma T., Kobata T. Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer. Gene Ther. 1998, 5:331-338.
22. Orbach A., Rachmilewitz J., Parnas M., Huang J.H., Tykocinski M.L., Dranitzki-Elhalel M. CTLA-4. FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals. J. Immunol. 2007, 179:7287-7294.
23. Pan R.Y., Chen S.L., Xiao X., Liu D.W., Peng H.J., Tsao Y.P. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum. 2000, 43:289-297.
24. Ruderman E.M., Pope R.M. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res. Ther. 2005, 7:21-25.
25. Schneider P., Holler N., Bodmer J.L., Hahne M., Frei K., Fontana A. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 1998, 187:1205-1213.
26. Shi W., Chen M., Xie L. Prolongation of corneal allograft survival by CTLA4-FasL in a murine model. Graefes. Arch. Clin. Exp. Ophthalmol. 2007, 245:1691-1697.
27. Sieg S., Smith D., Kaplan D. Differential activity of soluble versus cellular Fas ligand: regulation by an accessory molecule. Cell Immunol. 1999, 195:89-95.
28. Tak P.P., Smeets T.J., Daha M.R., Kluin P.M., Meijers K.A., Brand R., Meinders A.E., Breedveld F.C. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 1997, 40:217-225.
29. Tanaka M., Itai T., Adachi M., Nagata S. Downregulation of Fas ligand by shedding. Nat. Med. 1998, 4:31-36.
30. Tanaka M., Suda T., Yatomi T., Nakamura N., Nagata S. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J. Immunol. 1997, 158:2303-2309.
31. van den Berg W.B. Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res. 2001, 3:18-26.
32. Vervoordeldonk M.J., Tak P.P. Cytokines in rheumatoid arthritis. Curr. Rheumatol. Rep. 2002, 4:208-217.
33. Vincenti F., Larsen C., Durrbach A., Wekerle T., Nashan B., Blancho G., Lang P., Grinyo J., Halloran P.F., Solez K., Hagerty D., Levy E., Zhou W., Natarajan K., Charpentier B. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 2005, 353:770-781.
34. Walker L.S., McLeod J.D., Boulougouris G., Patel Y.I., Hall N.D., Sansom D.M. Down-regulation of CD28 via Fas (CD95): influence of CD28 on T-cell apoptosis. Immunology 1998, 94:41-47.
35. Wu Z., Wu X., Cao H., Dong X., Wang H., Hou Y. A novel and highly efficient production system for recombinant adeno-associated virus vector. Sci. China C Life Sci. 2002, 45:96-104.
36. Yao Q., Glorioso J.C., Evans C.H., Robbins P.D., Kovesdi I., Oligino T.J., Ghivizzani S.C. Adenoviral mediated delivery of FAS ligand to arthritic joints causes extensive apoptosis in the synovial lining. J. Gene Med. 2000, 2:210-219.
37. Zhang H., Gao G., Clayburne G., Schumacher H.R. Elimination of rheumatoid synovium in situ using a Fas ligand 'gene scalpel'. Arthritis Res. Ther. 2005, 7:R1235-R1243.
38. Zhang H., Yang Y., Horton J.L., Samoilova E.B., Judge T.A., Turka J.M., Chen Y. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J. Clin. Invest. 1997, 100:1951-1957.